Tafenoquine
- Generic Name
- Tafenoquine
- Brand Names
- Arakoda, Krintafel
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28F3N3O3
- CAS Number
- 106635-80-7
- Unique Ingredient Identifier
- 262P8GS9L9
- Background
Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group. It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture. It was FDA approved on July 20, 2018.
- Indication
用于16岁及以上疟疾患者，根治(预防复发)由间日疟原虫(P.vivax)导致的疟疾。
- Associated Conditions
- Malaria caused by plasmodium vivax
AI-Driven Discovery Unveils Cancer Therapy Breakthrough
Rakovina Therapeutics Inc. has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments, potentially reshaping oncology research.
60 Degrees Pharma's Tafenoquine Receives IRB Approval for Phase II Chronic Babesiosis Study
• 60 Degrees Pharmaceuticals has received IRB approval for a Phase II study evaluating Tafenoquine for chronic babesiosis.
• The open-label study will assess the efficacy and safety of Tafenoquine over 90 days in patients with chronic babesiosis.
• Patient enrollment is expected to commence in Q3 2025, targeting those with significant functional impairment for at least six months.
• The company estimates a substantial addressable market for Tafenoquine in babesiosis, potentially exceeding 400,000 patients by 2035.
60 Degrees Pharma's Tafenoquine Study for Babesiosis in Immunocompromised Patients Gains IRB Approval
• 60 Degrees Pharma received IRB approval for an expanded access study of tafenoquine to treat persistent babesiosis in immunocompromised patients.
• The study aims to validate an 80% cure rate observed in a previous Yale School of Public Health case series using tafenoquine.
• Tafenoquine, approved for malaria prophylaxis as ARAKODA, is being investigated for a new indication to treat babesiosis.
• The company plans to file an NDA with the FDA in Q2 2026 for tafenoquine as a treatment for babesiosis, targeting acute and chronic cases.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath